Ganymed Pharmaceuticals Ag

Biontech Ag

Johannes Gutenberg-Universität Mainz

Astellas Pharma Gmbh

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Ganymed Pharmaceuticals Gmbh

Biontech Se

Johannes Gutenberg Universität

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

Tron-Translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz

Biontech Cell & Gene Therapies Gmbh

Tron—translationale Onkologie an Der Universitat

Tron—translationale Onkologie an Der Universitätmedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh

Biotech Cell & Gene Thrapies Gmbh

Universitätsmedizin Der Johannes Gutenberg-Universitat Mainz

Özlem Türeci

Ugur Sahin

Michael Koslowski

Dirk Usener

Gerd Helftenbein

Volker Schlüter

Harald-Gerhard Geppert

Stefan Fritz

Korden Walter

Gunda Brandenburg

Anja Kristina Schröder

Phillippe Thiel

Christoph Uherek

Sebastian Kreiter

Rita Mitnacht-Kraus

Maria Kreuzberg

Stefan Woll

Markus Fiedler

Alexander Muik

Andreas Kuhn

Bernd Hubner

Michael Erdeljan

Kerstin Walzer

Philippe Thiel

Petra Simon

Tana Omokoko

Christiane Regina Stadler

Ralf-Holger Voss

Stefan Jacobs

Tim Beissert

Fabrice Le Gall

Thorsten Klamp

Thomas Michael Hiller

Karolina Anna Mroz

Jens Schumacher

Stefan Wöll

Annette Vogel

Sandra Schneider

Alptekin Güler

Stephanie Hein

Kathleen Hobohm

Cornelia Heinz

Holger Hoff

Cornelia Adriana Maria Heinz

Magdalena Jadwiga Utsch

Daniel Maurus

Arne Jendretzki

Sylvia Luxen

Sonja Witzel

Andrea Breitkreuz

Silke Holtkamp

Petra Oehm

Julia Holland

Hayat Bähr-Mahmud

Laura Plum

Meike Wagner

Lisa Hebich

Gabriela-Elena Oprea

Torsten Seppmann

Abderraouf Selmi

Alexander Zaigler

Leyla Fischer

Sabine HÄCKER

Michael Weichel

Walter Korden

Stefan Denis Jacobs

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

Coronavirus vaccine

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject. i.e., vaccine RNA encoding vaccine antigen.

The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.

Antibodies useful in cancer diagnosis

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing Claudin-6 (CLDN6), including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.

Antibodies specific for claudin 6 (CLDN6)

The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.

Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.

Monoclonal antibodies against Claudin-18 for treatment of cancer

The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.

Therapy involving antibodies against Claudin 18.2 for treatment of cancer

The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.

Claudin-6-specific immunoreceptors and t cell epitopes

Monoclonal antibodies against claudin-18 for treatment of cancer

The present technology relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the present technology also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.

Genetic products differentially expressed in tumors and the use thereof

Claudin-6-specific immunoreceptors and T cell epitopes

The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.

Identification of tumor-associated markers for diagnosis and therapy

Growing community of inventors

Mainz, Germany

Özlem Türeci